Any current/future new fundraising through debt or equity?

Vikas Agarwal confirmed that the company is actively monitoring acquisition opportunities but did not explicitly mention new fundraising through debt or equity at present. The company is finalizing partnerships with large NBFCs to support financing for customers and channel partners, indicating some external financial collaboration but not direct fundraising. No explicit statements about raising fresh equity or debt capital were made in the provided transcript excerpts. Capex guidance for FY25 or FY26 is not provided, suggesting cautious approach to large capital raising currently. Overall, th

Any current/future capex/capital investment/strategic investment?

The company is exploring opening a warehouse in Indore but has not yet opened it, focusing first on optimizing existing warehouses (Page 12). They are building a tech stack for Smileworks dental lab to enable direct ordering and tracking of prostheses, tapping a unique market opportunity (Page 11). Smileworks lab was acquired and merged from an existing lab with plans to scale operations pan India (Page 13). No specific capex guidance was given for FY25 or FY26 (Page 11). Intentions to increase marketing budgets and invest in offline marketing were stated, implying ongoing strategic investment

Future growth expectations in sales/revenue/volumes?

FY26 revenue growth expectation is a basic 30% growth over FY25, with aspirations for higher growth (Page 12). Long-term revenue target includes reaching around INR500 crores by FY27, though no definitive guidance is given (Page 12). The company is inclined to reach INR800 crores and beyond in the longer term, with a motivated team focused on this goal (Page 7). Own brand mix is targeted to rise to around 70% in 3-4 years, which would support margin and revenue growth (Page 8). Market potential is large, including a USD3 billion dental lab market by 2030, with new initiatives like Smileworks l

Future growth expectations in earnings/operating earnings/profits/EPS?

Company targets basic revenue growth of around 30% for FY26 over FY25, with aspirations for higher growth. Long-term revenue target is around INR 500 crores by FY27, with potential to reach INR 800 crores or more beyond that. EBITDA margins improved to approximately 11% in recent quarter, with exploration to sustain or enhance margins. Net profit margins temporarily impacted by investment in talent and infrastructure but expected to improve as revenues grow. Earnings per share increased by ~30.78% year-on-year in H1 FY25, indicating strong bottom-line growth potential. Focus on incre

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders by exact figures. However, operational metrics indicate growth in orders: 2.61 lakh total orders in H1 FY25, a 29% increase year-on-year. Monthly active users increased 48% to 3.35 lakh, reflecting strong engagement and potential for order growth. Inventory and warehousing improvements aim to support faster delivery timelines and higher order fulfillment efficiency. Focus on expanding product range and improving logistics suggests an expectation of increasing order volumes. Private label and offline

Vasa Denticity LtdQ2 FY25Healthcare Equipment & Supplies

Vasa Denticity Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹434.8P/E: 62.3Market Cap: ₹753 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

FY26 revenue growth expectation is a basic 30% growth over FY25, with aspirations for higher growth (Page 12).
Long-term revenue target includes reaching around INR500 crores by FY27, though no definitive guidance is given (Page 12).
The company is inclined to reach INR800 crores and beyond in the longer term, with a motivated team focused on this goal (Page 7).
Own brand mix is targeted to rise to around 70% in 3-4 years, which would support margin and revenue growth (Page 8).
Market potential is large, including a USD3 billion dental lab market by 2030, with new initiatives like Smileworks lab expected to contribute growth (Pages 12-13).
The online dental market is expected to grow to 40% of the total industry in 10 years, with a hybrid online-offline model planned to capture this opportunity (Page 14).
Growth depends on optimizing inventory, expanding product catalogue (target 35,000 products), and infrastructure improvements to improve delivery and customer satisfaction (Pages 5-7).

Margin guidance

Category 3

Company targets basic revenue growth of around 30% for FY26 over FY25, with aspirations for higher growth.
Long-term revenue target is around INR 500 crores by FY27, with potential to reach INR 800 crores or more beyond that.
EBITDA margins improved to approximately 11% in recent quarter, with exploration to sustain or enhance margins.
Net profit margins temporarily impacted by investment in talent and infrastructure but expected to improve as revenues grow.
Earnings per share increased by ~30.78% year-on-year in H1 FY25, indicating strong bottom-line growth potential.
Focus on increasing own brand mix to 70% over 3 years to improve profitability and margin stability.
Investments in marketing, product portfolio, and logistics expected to drive higher customer acquisition and revenue growth.
Overall, management optimistic about sustainable long-term growth in earnings and profitability.

See what Vasa Denticity Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Vikas Agarwal confirmed that the company is actively monitoring acquisition opportunities but did not explicitly mention new fundraising through debt or equity at present.
The company is finalizing partnerships with large NBFCs to support financing for customers and channel partners, indicating some external financial collaboration but not direct fundraising.
No explicit statements about raising fresh equity or debt capital were made in the provided transcript excerpts.
Capex guidance for FY25 or FY26 is not provided, suggesting cautious approach to large capital raising currently.
Overall, there is openness to strategic deals and financial partnerships, but no concrete indication of imminent equity or debt fundraising.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders by exact figures.
However, operational metrics indicate growth in orders: 2.61 lakh total orders in H1 FY25, a 29% increase year-on-year.
Monthly active users increased 48% to 3.35 lakh, reflecting strong engagement and potential for order growth.
Inventory and warehousing improvements aim to support faster delivery timelines and higher order fulfillment efficiency.
Focus on expanding product range and improving logistics suggests an expectation of increasing order volumes.
Private label and offline channel expansion indicate efforts to boost order book through multiple sales channels.
Management is tracking inventory at SKU and warehouse levels to optimize order fulfillment.
No direct statements on backlog or pending orders were mentioned.

See what Vasa Denticity Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is exploring opening a warehouse in Indore but has not yet opened it, focusing first on optimizing existing warehouses (Page 12).
They are building a tech stack for Smileworks dental lab to enable direct ordering and tracking of prostheses, tapping a unique market opportunity (Page 11).
Smileworks lab was acquired and merged from an existing lab with plans to scale operations pan India (Page 13).
No specific capex guidance was given for FY25 or FY26 (Page 11).
Intentions to increase marketing budgets and invest in offline marketing were stated, implying ongoing strategic investment in market expansion (Page 14).
Investments in talent increased by 50% in the past year to build infrastructure and capabilities (Page 6).
The company is working on inventory management improvements and logistics expansion to reduce delivery timelines (Pages 5-6).
Opportunities for acquisitions are being evaluated continuously (Page 13).

Track Vasa Denticity Ltd — get its next earnings analysis in your feed

How does Vasa Denticity Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisVasa Denticity Ltd

Rev 2Mar 3

See where Vasa Denticity Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Vasa Denticity Ltd rank in Healthcare Equipment & Supplies?

Compare Vasa Denticity Ltd against every Healthcare Equipment & Supplies company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Vasa Denticity Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec

Compare:vs Poly Medicure Ltd vs Molbio Diagnosti vs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →